Liporaxel is named as an intervention in 3 current clinical trials in our China and South Korea registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Shanghai Pulmonary Hospital, Shanghai, China (1). The most-studied condition is NSCLC (Non-small Cell Lung Cancer).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
NCT07754812 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)
|
Phase 4 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | China |
|
GIST Oral Paclitaxel(Liporaxel)
NCT06326346 · ClinicalTrials.gov ↗ · Gastrointestinal Stromal Tumors
|
Phase 2 | Recruiting | Asan Medical Center | South Korea |
|
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
NCT03315364 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Breast Cancer
|
Phase 2/3 | Active, closed | Daehwa Pharmaceutical Co., Ltd | China, South Korea |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Pulmonary Hospital, Shanghai, China | 1 |
| Daehwa Pharmaceutical Co., Ltd | 1 |
| Asan Medical Center | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in South Korea | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and South Korea registers name Liporaxel as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in China and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Pulmonary Hospital, Shanghai, China (1), Daehwa Pharmaceutical Co., Ltd (1) and Asan Medical Center (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Liporaxel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Liporaxel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Liporaxel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.